295P Overview of (neo)adjuvant systemic therapy treatment studies in (ultra-)rare cancers versus common cancers

ESMO rare cancers. 2026 Open access

Read full text
Authors: Léon J. J. A. Gerridzen, Eelke Hiddo Gort, W. Minnaard, C M L van Herpen
DOI: 10.1016/j.esmorc.2026.100220
Cited by: 0

Abstract

The 5-year survival rates for rare cancers (RCs) are poor when compared to common cancers (CCs), and this gap is increasing. In oncology, adjuvant and neoadjuvant therapies are used to increase the likelihood of curation. The aim of this study is to investigate the number of clinical studies concerning the use of (neo)adjuvant systemic therapies ((N)AT) for RCs compared to CCs. Furthermore, we reviewed the recommendations regarding (N)AT in clinical practice guidelines for RCs and CCs, to identify potential impact of a difference in the number of (N)AT studies.

Fields of Study & Subjects

Global Cancer Incidence and Screening Pancreatic and Hepatic Oncology Research Statistical Methods in Clinical Trials

Publication details

Journal / source
ESMO rare cancers.
Volume
5
Pages
100220–100220
Publication date
1 March 2026
Language
EN